Works matching IS 0741238X AND DT 2022 AND VI 39 AND IP 4


Results: 30
    1
    2

    Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.

    Published in:
    Advances in Therapy, 2022, v. 39, n. 4, p. 1810, doi. 10.1007/s12325-022-02068-7
    By:
    • Wray, Sibyl;
    • Then Bergh, Florian;
    • Wundes, Annette;
    • Arnold, Douglas L.;
    • Drulovic, Jelena;
    • Jasinska, Elzbieta;
    • Bowen, James D.;
    • Negroski, Donald;
    • Naismith, Robert T.;
    • Hunter, Samuel F.;
    • Gudesblatt, Mark;
    • Chen, Hailu;
    • Lyons, Jennifer;
    • Shankar, Sai L.;
    • Kapadia, Shivani;
    • Mendoza, Jason P.;
    • Singer, Barry A.
    Publication type:
    Article
    3

    Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers.

    Published in:
    Advances in Therapy, 2022, v. 39, n. 4, p. 1743, doi. 10.1007/s12325-022-02067-8
    By:
    • Casajús, Ana;
    • Zubiaur, Pablo;
    • Méndez, Marta;
    • Campodónico, Diana;
    • Gómez, Antía;
    • Navares-Gómez, Marcos;
    • Villapalos-García, Gonzalo;
    • Soria-Chacartegui, Paula;
    • Novalbos, Jesús;
    • Román, Manuel;
    • Mejía-Abril, Gina;
    • Ochoa, Dolores;
    • Abad-Santos, Francisco
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    16
    17
    18
    19
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30